Tilray Brands Inc
Change company Symbol lookup
Select an option...
TLRY Tilray Brands Inc
MHI Pioneer Municipal High Income Fund, Inc.
GLW Corning Inc
PAYS Paysign Inc
ALTR Altair Engineering Inc
CVX Chevron Corp
ASCB ASPAC II Acquisition Corp
STRS Stratus Properties Inc
ESMC Escalon Medical Corp
ATO Atmos Energy Corp
Go

Health Care : Pharmaceuticals | Mid Cap Value
Based in Canada
Company profile

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: cannabis business, distribution business, beverage alcohol business, and wellness business. The cannabis business segment is engaged in the cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The distribution business segment is engaged in the purchase and resale of pharmaceutical and wellness products. The beverage alcohol business segment is engaged in the production, marketing, and sale of beverage alcohol products. The wellness business segment is engaged in the production, marketing and distribution of hemp-based food and other wellness products. It offers a broad-based portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. It is also a hemp food manufacturer. It has operations in Canada, the United States, Europe, Australia, and Latin America.

Closing Price
$2.75
Day's Change
-0.11 (-3.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.92
Day's Low
2.75
Volume
(Light)
Volume:
11,862,163

10-day average volume:
15,929,589
11,862,163

Tilray Brands, Inc. Reports Record Fiscal Year 2022 Results

4:26 pm ET July 28, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:TLRY),(TSX:TLRY), EQNX::TICKER_END FY2022 Net Revenue Grew 22% to $628 Million Compared to the Prior Year; On a Constant Currency Basis, Net Revenue Increased by 29%

Fourth Quarter Net Revenue Grew 8% to $153 Million Compared to the Prior Year Period; On a Constant Currency Basis, Net Revenue Increased by 14% to $163 Million

Company Expects to Generate $70-$80 Million of Adjusted EBITDA and be Free-Cash Flow Positive in Its Operating Business Units in FY2023

Foundation in Place for Profitable and Sustainable Growth

Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported financial results for the fourth quarter and full fiscal year ended May 31, 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated, and presented in accordance with accounting principles generally accepted in the U.S. ("GAAP").

Irwin D. Simon, Tilray Brands' Chairman and Chief Executive Officer, stated, "Over the past year, we have accelerated the optimization of our operations and sharpened execution against our most profitable core business opportunities in medical, adult-use, wellness, and beverage-alcohol across Canada, Europe, and the U.S. At the same time, we accelerated our growth potential through tactical execution and strategic initiatives that enable accelerated revenue growth through improved cultivation, brand building, and distribution. These actions should also contribute to bottom-line performance improvement through production efficiencies and cost reductions. The outcome of this work is that we have driven top line growth across our markets, significantly improved our operating performance, and strengthened our balance sheet."

He continued, "We are confident that our proactive steps to plan for the evolution of the cannabis business in each of our markets has positioned Tilray Brands to be at the forefront of the industry on a global basis while delivering profitability and driving shareholder value."

Financial Highlights - 2022 Fiscal Fourth Quarter

Financial Highlights- 2022 Fiscal Year

Cost-Saving Synergies and Strengthened Balance Sheet

Since the closing of the Tilray-Aphria transaction, the Company has delivered $85 million in cost synergies, exceeding its original target of delivering $80 million of cost savings by the end of fiscal year 2023. These synergies are due to consolidation in key areas of cultivation and production, cannabis and product purchasing, sales and marketing, and corporate expenses. The Company has subsequently identified an additional $20 million of savings, and now expects to deliver a total of $100 million in cost synergies from the transaction by the end of fiscal year 2023.

Further, with the benefit of an additional $80 million of shared cost savings, synergies and financial benefits over the next two years associated with the HEXO transaction, management expects that Tilray Brands will be free cash flow positive in its business units in fiscal year 2023.

Upside Potential of HEXO Transaction

Tilray Brands' acquisition of HEXO Corp.'s senior secured convertible note, on highly favorable terms, closed on July 12, 2022, bringing immediate accretion to the Company and facilitating collaboration and the sharing of best practices that will help Tilray Brands to drive ongoing international expansion and take advantage of the opportunities expected to come with federal legalization in the U.S. In addition, due to significant operating efficiencies, the companies expect to deliver a total of $80 million of shared cost savings over the next two years.

Highlights of Strategic Growth Actions in Fiscal 2022

United States:

Canada:

Europe and International:

Webcast

Tilray Brands will host a webcast to discuss these results today at 8:30 a.m. ET. Investors may join the live webcast available on the Investors section of the Company's website at www.tilray.com. The webcast will also be archived after the call concludes.

About Tilray Brands

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better - one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Patients and consumers trust Tilray Brands to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality and beloved brands that address the needs of the consumers, customers and patients we serve. A pioneer in cannabis research, cultivation, and distribution, Tilray Brands' unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on Tilray Brands, visit www.Tilray.com and follow @Tilray

Cautionary Statement Concerning Forward-Looking Statements

Certain statements in this press release constitute forward-looking information or forward-looking statements (together, "forward-looking statements") under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements can be identified by words such as "forecast," "future," "should," "could," "enable," "potential," "contemplate," "believe," "anticipate," "estimate," "plan," "expect," "intend," "may," "project," "will," "would" and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.

Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company's ability to become the world's leading cannabis-focused consumer branded company and achieve $4B in revenue by the end of fiscal 2024; the Company's ability to generate $70-$80 million of Adjusted EBITDA and expectation to be free-cash flow positive in its operating business units in FY 2023; the Company's ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular markets, including in Canada, the U.S. and the EU; and the Company's ability to successfully achieve the expected production efficiencies, synergies and cost savings relating to the HEXO transactions and agreed commercial arrangements; and the Company's anticipated investments, including in organic and strategic growth, partnership efforts, product offerings and other initiatives.

Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Use of Non-U.S. GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures, including adjusted gross margin, Adjusted EBITDA and free cash flow. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company's operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company's Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.

Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, impairments, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company's GAAP financial results.

The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company's consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year.

Adjusted EBITDA is calculated as net income (loss) before inventory valuation adjustments; interest expenses, net; other expenses (income), net; deferred income tax (recoveries) expenses, current income tax expenses (benefit); foreign exchange gain (loss), net; depreciation and amortization expenses; stock-based compensation expenses; loss from equity method investments; loss on disposal of property and equipment; amortization of inventory step-up; severance costs; impairment of assets; and change in fair value of warrant liability. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Gross margin, excluding inventory valuation adjustments, is calculated as revenue less cost of sales adjusted to add back inventory valuation adjustments and amortization of inventory step-up, divided by revenue. A reconciliation of Gross margin, excluding inventory valuation adjustments, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Free cash flow is comprised of two GAAP measures deducted from each other which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.

For further information:

Media: Berrin Noorata, news@tilray.com

Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com

This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. Reconciliations of non-GAAP financial measures to GAAP financial measures and other non-GAAP financial calculations are provided herein in the tables.

Consolidated Statements of Financial Position

(In thousands of United States dollars)                                                                                                   May 31, 2022         May 31, 2021
Assets
Current assets
Cash and cash equivalents                                                                                                                 $    415,909         $    488,466
Accounts receivable, net                                                                                                                       95,279               87,309
Inventory                                                                                                                                      245,529              256,429
Prepaids and other current assets                                                                                                              46,786               48,920
Current portion of convertible notes receivable                                                                                                --                   2,485
Total current assets                                                                                                                           803,503              883,609
Capital assets                                                                                                                                 587,499              650,698
Right-of-use assets                                                                                                                            12,996               18,267
Intangible assets                                                                                                                              1,277,875            1,605,918
Goodwill                                                                                                                                       2,641,305            2,832,794
Interest in equity investees                                                                                                                   4,952                8,106
Long-term investments                                                                                                                          10,050               17,685
Convertible notes receivable                                                                                                                   111,200              --
Other assets                                                                                                                                   314                  8,285
Total assets                                                                                                                              $    5,449,694       $    6,025,362
Liabilities
Current liabilities
Bank indebtedness                                                                                                                         $    18,123          $    8,717
Accounts payable and accrued liabilities                                                                                                       157,431              212,813
Contingent consideration                                                                                                                       16,007               60,657
Warrant liability                                                                                                                              14,255               78,168
Current portion of lease liabilities                                                                                                           6,703                4,264
Current portion of long-term debt                                                                                                              67,823               36,622
Total current liabilities                                                                                                                      280,342              401,241
Lease liabilities                                                                                                                              11,329               53,946
Long-term debt                                                                                                                                 117,879              167,486
Convertible debentures                                                                                                                         401,949              667,624
Deferred tax liabilities, net                                                                                                                  196,638              265,845
Other liabilities                                                                                                                              191                  3,907
Total liabilities                                                                                                                              1,008,328            1,560,049
Commitments and contingencies (refer to Note 17)
Stockholders' equity
Common stock ($0.0001 par value; 990,000,000 shares authorized; 532,674,887 and 446,440,641 shares issued and outstanding, respectively)       53                   46
Additional paid-in capital                                                                                                                     5,382,367            4,792,406
Accumulated other comprehensive (deficit) income (loss)                                                                                        (20,764   )          152,668
Accumulated deficit                                                                                                                            (962,851  )          (486,050  )
Total Tilray Brands, Inc. stockholders' equity                                                                                                 4,398,805            4,459,070
Non-controlling interests                                                                                                                      42,561               6,243
Total stockholders' equity                                                                                                                     4,441,366            4,465,313
Total liabilities and stockholders' equity                                                                                                $    5,449,694       $    6,025,362

Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)

(In thousands of United States dollars, excpet for per share data)  For the three months ended May 31,     For the year ended May 31,
                                                                         2022                2021              2022              2021
Net revenue                                                         $    153,325        $    142,236       $   628,372       $   513,085
Cost of goods sold                                                       160,058             119,738           511,555           389,903
Gross profit                                                             (6,733   )          22,498            116,817           123,182
Operating expenses:
General and administrative                                               41,400              32,839            162,801           111,575
Selling                                                                  9,643               8,525             34,926            26,576
Amortization                                                             30,846              16,100            115,191           35,221
Marketing and promotion                                                  10,771              5,103             30,934            17,539
Research and development                                                 54                  358               1,518             830
Change in fair value of contingent consideration                         (15,585  )          --                (44,650  )        --
Impairment                                                               378,241             --                378,241           --
Litigation costs                                                         4,099               2,099             16,518            3,251
Transaction costs                                                        1,221               31,161            31,739            60,361
Total operating expenses                                                 460,690             96,185            727,218           255,353
Operating loss                                                           (467,423 )          (73,687 )         (610,401 )        (132,171 )
Interest expense, net                                                    (5,522   )          (9,466  )         (27,944  )        (27,977  )
Non-operating income (expense), net                                      11,342              121,510           197,671           (184,838 )
Loss before income taxes                                                 (461,603 )          38,357            (440,674 )        (344,986 )
Income taxes (recovery)                                                  (3,803   )          4,735             (6,542   )        (8,972   )
Net loss                                                            $    (457,800 )     $    33,622        $   (434,132 )    $   (336,014 )
Net loss per share - basic and diluted                              $    (0.90    )     $    0.38          $   (0.90    )    $   (1.25    )

Net Revenue by Operating Segment

(In thousands of United States dollars)  Year Ended May 31, 2022          % of Total Revenue  Year Ended May 31, 2022          % of Total Revenue
Cannabis business                        $               237,522          38        %         $               201,392          39        %
Distribution business                                    259,747          42        %                         277,300          54        %
Beverage alcohol business                                71,492           11        %                         28,599           6         %
Wellness business                                        59,611           9         %                         5,794            1         %
Net revenue                              $               628,372          100       %         $               513,085          100       %
(In thousands of United States dollars)  Three months ended May 31, 2022  % of Total Revenue  Three months ended May 31, 2021  % of Total Revenue
Cannabis business                        $               53,253           35        %         $               53,703           38        %
Distribution business                                    61,160           39        %                         66,792           47        %
Beverage alcohol business                                22,727           15        %                         15,947           11        %
Wellness business                                        16,185           11        %                         5,794            4         %
Net revenue                              $               153,325          100       %         $               142,236          100       %

Net Cannabis Revenue by Market Channel

(In thousands of United States dollars)            For the year ended May 31,          For the year ended May 31,
                                                         2022       2022                     2021       2021
Revenue from Canadian medical cannabis products    $     30,599     13    %            $     25,539     13    %
Revenue from Canadian adult-use cannabis products        209,501    88    %                  222,930    110   %
Revenue from wholesale cannabis products                 6,904      3     %                  6,615      3     %
Revenue from international cannabis products             53,887     23    %                  9,250      5     %
Less excise taxes                                        (63,369 )  -27   %                  (62,942 )  -31   %
Total                                              $     237,522    100   %            $     201,392    100   %
                                                   For the three months ended May 31,  For the three months ended May 31,
(In thousands of United States dollars)                  2022       2022                     2021       2021
Revenue from Canadian medical cannabis products    $     7,246      14    %            $     6,968      13    %
Revenue from Canadian adult-use cannabis products        46,869     88    %                  59,710     111   %
Revenue from wholesale cannabis products                 141        0     %                  56         0     %
Revenue from international cannabis products             14,095     26    %                  4,623      9     %
Less excise taxes                                        (15,098 )  -28   %                  (17,654 )  -33   %
Total                                              $     53,253     100   %            $     53,703     100   %

Gross Margin and Adjusted Gross Margin

(In thousands of United States dollars)  For the year ended May 31, 2022
                                         Cannabis       Beverage      Distribution       Wellness      Total
Revenue                                  $  300,891     $  74,959     $    259,747       $  59,611     $  695,208
Excise taxes                                (63,369 )      (3,467 )        --               --            (66,836 )
Net revenue                                 237,522        71,492          259,747          59,611        628,372
Cost of goods sold                          194,834        32,033          243,231          41,457        511,555
Gross profit                                42,688         39,459          16,516           18,154        116,817
Gross margin                                18.0    %      55.2   %        6.4     %        30.5   %      18.6    %
Adjustments:
Inventory valuation adjustments             59,500         --              7,500            --            67,000
Purchase price accounting step-up           --             2,214           --               --            2,214
Adjusted gross profit                       102,188        41,673          24,016           18,154        186,031
Adjusted gross margin                       43.0    %      58.3   %        9.2     %        30.5   %      29.6    %
(In thousands of United States dollars)  For the year ended May 31, 2021
                                         Cannabis       Beverage      Distribution       Wellness      Total
Revenue                                  $  264,334     $  29,661     $    277,300       $  5,794      $  577,089
Excise taxes                                (62,942 )      (1,062 )        --               --            (64,004 )
Net revenue                                 201,392        28,599          277,300          5,794         513,085
Cost of goods sold                          130,511        12,687          242,472          4,233         389,903
Gross profit                                70,881         15,912          34,828           1,561         123,182
Gross margin                                35.2    %      55.6   %        12.6    %        26.9   %      24.0    %
Adjustments:
Inventory valuation adjustments             19,919         --              --               --            19,919
Purchase price accounting step-up           --             835             --               --            835
Adjusted gross profit                       90,800         16,747          34,828           1,561         143,936
Adjusted gross margin                       45.1    %      58.6   %        12.6    %        26.9   %      28.1    %
(In thousands of United States dollars)  For the three months ended May 31, 2022
                                         Cannabis       Beverage      Distribution       Wellness      Total
Revenue                                  $  68,351      $  23,459     $    61,160        $  16,185     $  169,155
Excise taxes                                (15,098 )      (732   )        --               --            (15,830 )
Net revenue                                 53,253         22,727          61,160           16,185        153,325
Cost of goods sold                          72,342         11,359          65,138           11,219        160,058
Gross profit                                (19,089 )      11,368          (3,978  )        4,966         (6,733  )
Gross margin                                -35.8   %      50.0   %        -6.5    %        30.7   %      -4.4    %
Adjustments:
Inventory valuation adjustments             47,500         --              7,500            --            55,000
Purchase price accounting step-up           --             2,214           --               --            2,214
Adjusted gross profit                       28,411         13,582          3,522            4,966         50,481
Adjusted gross margin                       53.4    %      59.8   %        5.8     %        30.7   %      32.9    %
(In thousands of United States dollars)  For the three months ended May 31, 2021
                                         Cannabis       Beverage      Distribution       Wellness      Total
Revenue                                  $  71,357      $  16,549     $    66,792        $  5,794      $  160,492
Excise taxes                                (17,654 )      (602   )        --               --            (18,256 )
Net revenue                                 53,703         15,947          66,792           5,794         142,236
Cost of goods sold                          49,731         5,350           60,424           4,233         119,738
Gross profit                                3,972          10,597          6,368            1,561         22,498
Gross margin                                7.4     %      66.5   %        9.5     %        26.9   %      15.8    %
Adjustments:
Inventory valuation adjustments             19,919         --              --               --            19,919
Purchase price accounting step-up           --             835             --               --            835
Adjusted gross profit                       23,891         11,432          6,368            1,561         43,252
Adjusted gross margin                       44.5    %      71.7   %        9.5     %        26.9   %      30.4    %

Adjusted Earnings before Interest, Taxes, and Amortization

(In thousands of United States dollars)           Three months ended May 31,          Year ended May 31,
Adjusted EBITDA reconciliation:                       2022              2021             2022            2021
Net loss                                          $   (457,800 )    $   33,622        $  (434,132 )   $  (336,014 )
Income taxes                                          (3,803   )        4,735            (6,542   )      (8,972   )
Interest expense, net                                 5,522             9,466            27,944          27,977
Non-operating expense (income), net                   (11,350  )        (121,510 )       (197,671 )      184,838
Amortization                                          40,768            24,540           154,592         67,832
Stock-based compensation                              8,969             5,937            35,994          17,351
Change in fair value of contingent consideration      (15,577  )        --               (44,650  )      --
Impairment                                            378,241           --               378,241         --
Inventory valuation adjustments                       55,000            19,919           67,000          19,919
Purchase price accounting step up                     2,214             835              2,214           835
Facility start-up and closure costs                   3,300             2,056            13,700          2,056
Lease expense                                         700               335              3,100           1,337
Litigation costs                                      4,099             2,099            16,518          3,251
Transaction costs                                     1,221             31,161           31,739          60,361
Adjusted EBITDA                                   $   11,504        $   13,195        $  48,047       $  40,771

Key Operating Metrics

                                                                                   For the three months ended May 31,    For the years ended May 31,
(In thousands of United States dollars)                                                 2022               2021              2022             2021
Net cannabis revenue                                                               $    53,253        $    53,703        $   237,522      $   201,392
Net beverage alcohol revenue                                                            22,727             15,947            71,492           28,599
Distribution revenue                                                                    61,160             66,792            259,747          277,300
Wellness revenue                                                                        16,185             5,794             59,611           5,794
Cannabis cost of sales                                                                  72,342             49,731            194,834          130,511
Beverage alcohol cost of sales                                                          11,359             5,350             32,033           12,687
Distribution cost of sales                                                              65,138             60,424            243,231          242,472
Wellness cost of sales                                                                  11,219             4,233             41,457           4,233
Gross profit (excluding inventory valuation adjustments and step-up)                    50,481             43,252            186,031          143,936
Cannabis gross margin (excluding inventory valuation adjustments and step-up)           53.4    %          44.5    %         43.0    %        45.1    %
Beverage gross margin (excluding inventory valuation adjustments and step-up)           59.8    %          71.7    %         58.3    %        58.6    %
Distribution gross margin (excluding inventory valuation adjustments and step-up)       5.8     %          9.5     %         9.2     %        12.6    %
Wellness gross margin (excluding inventory valuation adjustments and step-up)           30.7    %          26.9    %         30.5    %        26.9    %
Adjusted EBITDA                                                                         11,504             13,195            48,047           40,771
Cash and cash equivalents                                                               415,909            488,466           415,909          488,466
Working capital                                                                         523,161            479,883           523,161          482,368

https://ml.globenewswire.com/media/2dbf85bb-5e30-4623-8f9b-931442240c05/small/tilraybrands-logo-fullcolor-rbg-horiz-01-png.png

https://ml.globenewswire.com/media/2dbf85bb-5e30-4623-8f9b-931442240c05/small/tilraybrands-logo-fullcolor-rbg-horiz-01-png.png

comtex tracking

COMTEX_411183097/2010/2022-07-28T16:26:23

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.